Apellis Reports Data from Phase Ib Study of Pegcetacoplan
Apellis Pharmaceuticals announced 24-month data from the Phase Ib APL2-103 study of pegcetacoplan (15 mg/0.1 mL), an investigational targeted C3 therapy, in patients with advanced geographic atrophy secondary to age-related macular degeneration and low vision. The main study assessed the safety of the Phase III formulation of the drug. The current post hoc analysis, including eight patients with at least 24 months of data, revealed the growth rate of GA lesions in the treated eye was 46 percent (mean square root) slower than the untreated fellow eye (p=0.007). Read more.
TeamedOn and AGTC Advance X-Linked Retinoschisis Gene Therapy
TeamedOn International and Applied Genetic Technologies announced a licensing agreement to advance a gene therapy to treat X-linked retinoschisis. Under the terms of the agreement, AGTC will provide TeamedOn with the clinical trial material, and pre-clinical and clinical data generated to develop AGTC’s investigational intravitreal gene therapy candidate, rAAV2tYF-CB-hRS1. Read more.
ProQR Treatment Shows Benefits in Leber’s
ProQR Therapeutics announced new findings in one patient that indicate vision improvement after treatment with sepofarsen in a clinical trial for CEP290-mediated Leber’s congenital amaurosis 10 (LCA10). The patient, homozygous for the c.2991+1655A>G mutation in CEP290, was part of a larger cohort in the Phase I/II clinical trial, and was studied for 15 months after intravitreal treatment with sepofarsen. The company says that measures of visual function and retinal structure—including visual acuity, light sensitivity and visual fields—reached a substantial efficacy peak near three months after injection and remained better than baseline at 15 months. View the study.
Spark Collaborates with Senti Bio to Bolster Gene Therapy Research
Spark Therapeutics announced a collaboration and option agreement with Senti Biosciences to apply Senti Bio’s gene circuit technology to the development of gene therapies directed toward specific cell types in the eye and other areas of the body.
B+L Announces Topline Results From Phase III NOV03 Trial
Bausch + Lomb announced topline data from the first Phase III trial (GOBI trial) evaluating the investigational topical drug NOV03 (perfluorohexyloctane) aimed at treating the signs and symptoms of dry-eye disease associated with meibomian gland dysfunction. In the topline data, the drug met both of its co-primary endpoints. Read more.
Santen Teams with Mass Eye and Ear & Ulster University
Santen announced a research initiative with scientists from Massachusetts Eye and Ear and Ulster University (UK) to research and develop novel treatments for glaucoma. Read more.
Complimentary CME Education Videos